Meinian Onehealth Healthcare Holdings Co., Ltd.

SZSE:002044 Stock Report

Market Cap: CN¥19.0b

Meinian Onehealth Healthcare Holdings Valuation

Is 002044 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002044 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002044 (CN¥4.89) is trading below our estimate of fair value (CN¥6.28)

Significantly Below Fair Value: 002044 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002044?

Key metric: As 002044 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002044. This is calculated by dividing 002044's market cap by their current earnings.
What is 002044's PE Ratio?
PE Ratio61.9x
EarningsCN¥307.13m
Market CapCN¥19.02b

Price to Earnings Ratio vs Peers

How does 002044's PE Ratio compare to its peers?

The above table shows the PE ratio for 002044 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.1x
600763 Topchoice Medical
44.8x16.7%CN¥21.8b
603882 Guangzhou Kingmed Diagnostics Group
89.6x44.9%CN¥14.4b
600682 Nanjing Xinjiekou Department Store
37.1x34.1%CN¥9.3b
300962 Zhongjin Irradiation
40.8xn/aCN¥4.4b
002044 Meinian Onehealth Healthcare Holdings
61.9x50.8%CN¥19.0b

Price-To-Earnings vs Peers: 002044 is expensive based on its Price-To-Earnings Ratio (61.9x) compared to the peer average (53.1x).

Price to Earnings Ratio vs Industry

How does 002044's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
002044 61.9xIndustry Avg. 32.8xNo. of Companies7PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 002044 is expensive based on its Price-To-Earnings Ratio (61.9x) compared to the CN Healthcare industry average (32.8x).

Price to Earnings Ratio vs Fair Ratio

What is 002044's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002044 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio61.9x
Fair PE Ratio48.4x

Price-To-Earnings vs Fair Ratio: 002044 is expensive based on its Price-To-Earnings Ratio (61.9x) compared to the estimated Fair Price-To-Earnings Ratio (48.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 002044 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥4.89
CN¥5.82
+19.0%
23.8%CN¥7.36CN¥4.00n/a3
Nov ’25CN¥4.69
CN¥5.53
+17.8%
23.7%CN¥7.20CN¥4.00n/a3
Oct ’25CN¥4.33
CN¥5.53
+27.6%
23.7%CN¥7.20CN¥4.00n/a3
Sep ’25CN¥3.47
CN¥6.88
+98.2%
9.1%CN¥7.43CN¥6.00n/a3
Aug ’25CN¥3.70
CN¥6.88
+85.9%
9.1%CN¥7.43CN¥6.00n/a3
Jul ’25CN¥3.77
CN¥6.88
+82.4%
9.1%CN¥7.43CN¥6.00n/a3
Jun ’25CN¥4.19
CN¥6.88
+64.1%
9.1%CN¥7.43CN¥6.00n/a3
May ’25CN¥4.42
CN¥7.76
+75.6%
5.2%CN¥8.09CN¥7.20n/a3
Apr ’25CN¥5.07
CN¥8.20
+61.7%
2.7%CN¥8.50CN¥8.00n/a3
Mar ’25CN¥5.63
CN¥8.20
+45.6%
2.7%CN¥8.50CN¥8.00n/a3
Feb ’25CN¥4.98
CN¥8.20
+64.6%
2.7%CN¥8.50CN¥8.00n/a3
Jan ’25CN¥6.01
CN¥8.43
+40.3%
3.9%CN¥8.80CN¥8.00n/a3
Dec ’24CN¥6.18
CN¥8.56
+38.5%
4.2%CN¥8.93CN¥8.00n/a4
Nov ’24CN¥6.21
CN¥8.56
+37.8%
4.2%CN¥8.93CN¥8.00CN¥4.694
Oct ’24CN¥6.80
CN¥8.48
+24.6%
4.5%CN¥8.93CN¥8.00CN¥4.333
Sep ’24CN¥6.83
CN¥8.48
+24.1%
4.5%CN¥8.93CN¥8.00CN¥3.473
Aug ’24CN¥7.18
CN¥8.48
+18.0%
4.5%CN¥8.93CN¥8.00CN¥3.703
Jul ’24CN¥7.11
CN¥7.96
+12.0%
12.1%CN¥8.93CN¥7.00CN¥3.772
Jun ’24CN¥6.48
CN¥7.96
+22.9%
12.1%CN¥8.93CN¥7.00CN¥4.192
Jan ’24CN¥6.13
CN¥5.00
-18.4%
20.0%CN¥6.00CN¥4.00CN¥6.012
Dec ’23CN¥5.49
CN¥5.00
-8.9%
20.0%CN¥6.00CN¥4.00CN¥6.182
Nov ’23CN¥4.40
CN¥5.00
+13.6%
20.0%CN¥6.00CN¥4.00CN¥6.212

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥6.7b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.53

7D

-5.8%

1Y

-34.9%

Innovita Biological Technology

CN¥5.7b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥41.72

7D

-2.1%

1Y

28.8%

Winner Medical

CN¥19.7b

Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.

300888

CN¥33.90

7D

5.4%

1Y

-14.7%